| Not Yet Recruiting | Pre-Radiation Chemotherapy for Newly Diagnosed High-Grade Glioma. NCT07439172 | The Cooper Health System | Phase 2 |
| Recruiting | HOBSCOTCH-CA (HOme-Based Self-management and COgnitive Training CHanges Lives in Brain CAncer) NCT06930846 | Dartmouth-Hitchcock Medical Center | N/A |
| Active Not Recruiting | Peds CHAMP1ON - Hematopoietic Stem Cell And Monoclonal Antibody PD-1 Blockade for RecurreNt Pediatric High-Gra NCT07031765 | University of Florida | Phase 1 |
| Recruiting | FearLess in NeuroOncology NCT06989086 | Virginia Commonwealth University | N/A |
| Recruiting | Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age NCT05956821 | University of Miami | Phase 1 / Phase 2 |
| Recruiting | Study of Olutasidenib and Temozolomide in HGG NCT06161974 | Rigel Pharmaceuticals | Phase 2 |
| Completed | CBT-I in Primary Brain Tumor Patients: Phase IIc Randomized Feasibility Pilot Trial NCT06439420 | Virginia Commonwealth University | Phase 2 |
| Suspended | Investigational Imaging Technique During Brain Surgery NCT05513859 | Emory University | N/A |
| Unknown | Ga-68 Prostate Specific Membrane Antigen PET/CT in Gliomas NCT06241391 | All India Institute of Medical Sciences, Bhubaneswar | N/A |
| Terminated | Prospective Evaluation of AI R&D Tool in Adult Glioma and Other Primary Brain Tumours (PEAR-GLIO) NCT06038760 | Ourotech, Inc. | — |
| Recruiting | SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance) NCT05303519 | Nuvation Bio Inc. | Phase 3 |
| Active Not Recruiting | Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma NCT05561374 | Oblato, Inc. | Phase 1 |
| Active Not Recruiting | Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma NCT05484622 | Institut de Recherches Internationales Servier | Phase 1 |
| Recruiting | Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Oli NCT05512351 | Henan Provincial People's Hospital | Phase 2 |
| Unknown | Hierarchical Diagnosis for Adult Diffuse Glioma Based on Deep Learning NCT05624736 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | — |
| Recruiting | All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma NCT05345002 | Stephen Bagley, MD, MSCE | Phase 2 |
| Withdrawn | Investigation of Oral OKN-007 in Recurrent High-grade Glioma Participants NCT03649464 | Oblato, Inc. | Phase 1 / Phase 2 |
| Recruiting | PRO-GLIO: PROton Versus Photon Therapy in IDH-mutated Diffuse Grade II and III GLIOmas NCT05190172 | Oslo University Hospital | N/A |
| Recruiting | A Randomized Trial of Delayed Radiotherapy in Patients Low-grade Oligodendrogliomas Requiring a Treatment Othe NCT04702581 | Hospices Civils de Lyon | Phase 3 |
| Unknown | Educating Brain Tumor Patients Using Patient-specific Actual-size Three-dimensional Printed Models NCT04970615 | Sümeyye Sezer | — |
| Recruiting | A Clinical Study to Improve Brain Function and Quality of Life of Patients With Newly Diagnosed Brain Tumors ( NCT05331521 | University Hospital Heidelberg | Phase 3 |
| Recruiting | Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms NCT04541082 | Jazz Pharmaceuticals | Phase 1 |
| Unknown | Proteomic Characterization of Aggressive Oligodendrogliomas NCT04843085 | Hospices Civils de Lyon | — |
| Withdrawn | Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolom NCT04105374 | NRG Oncology | Phase 2 / Phase 3 |
| Recruiting | Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) G NCT04623931 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Radiotherapy in IDH Mutated Glioma: Evaluation of Late Outcomes NCT04304300 | Erasmus Medical Center | — |
| Withdrawn | Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Re NCT03014804 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Completed | Social Determinants of Health in Glioblastoma Population NCT03900689 | Wake Forest University Health Sciences | — |
| Unknown | The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor NCT03896958 | SpeciCare | — |
| Terminated | Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases NCT03796273 | Wake Forest University Health Sciences | EARLY_Phase 1 |
| Active Not Recruiting | Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant NCT03180502 | NRG Oncology | Phase 2 |
| Recruiting | Proton Therapy Research Infrastructure- ProTRAIT- Neuro-oncology NCT04648462 | Maastricht Radiation Oncology | — |
| Withdrawn | NovoTTF-200A Device in Treating Patients With Newly Diagnosed High Risk Oligodendroglioma NCT03353896 | University of Southern California | N/A |
| Active Not Recruiting | A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2 NCT03152318 | Dana-Farber Cancer Institute | Phase 1 |
| Terminated | A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG) NCT02924038 | Nicholas Butowski | Phase 1 |
| Completed | RRx-001 + Radiation + Temozolomide In Newly Diagnosed Glioblastoma and Anaplastic Gliomas NCT02871843 | EpicentRx, Inc. | Phase 1 |
| Withdrawn | Autologous Stem Cell Collection and Reinfusion in Newly Diagnosed High Grade Gliomas NCT02976441 | Washington University School of Medicine | EARLY_Phase 1 |
| Completed | Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma NCT02549833 | Jennie Taylor | Phase 1 |
| Terminated | First in Patient Study for PF-06840003 in Malignant Gliomas NCT02764151 | Pfizer | Phase 1 |
| Completed | Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response Durin NCT02747407 | Wake Forest University Health Sciences | — |
| Completed | Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With NCT02530320 | Grupo Español de Investigación en Neurooncología | Phase 2 |
| Terminated | Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance De NCT02372409 | Washington University School of Medicine | Phase 2 |
| Unknown | A Prospective Cohort to Study the Effect of Temozolomide on IDH Mutational Low Grade Gliomas NCT02209428 | Huashan Hospital | Phase 2 |
| Terminated | Evaluating the Expression Levels of MicroRNA-10b in Patients With Gliomas NCT01849952 | Dartmouth-Hitchcock Medical Center | — |
| Terminated | Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors NCT01836549 | Pediatric Brain Tumor Consortium | Phase 2 |
| Completed | Neural Basis of Language Processing NCT02903784 | University Hospital, Montpellier | N/A |
| Recruiting | Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma NCT01649830 | Sun Yat-sen University | Phase 3 |
| Completed | Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors NCT01609790 | National Cancer Institute (NCI) | Phase 2 |
| Completed | HLA-A2-Restricted Glioma Antigen-Peptides Vaccinations With Poly-ICLC for Recurrent WHO Grade II Gliomas NCT00874861 | Ian F. Pollack, M.D. | EARLY_Phase 1 |
| Unknown | A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma NCT00683761 | TransMolecular | Phase 1 / Phase 2 |
| Unknown | FET-PET for Diagnosis and Monitoring in Patients With Low Grade Glioma NCT01089244 | Ludwig-Maximilians - University of Munich | — |
| Unknown | Safety and Dose-Finding Study of TM-601 in Adults With Recurrent Malignant Glioma NCT00591058 | TransMolecular | Phase 1 |
| Terminated | A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplast NCT00389090 | Keryx / AOI Pharmaceuticals, Inc. | Phase 2 |
| Completed | Efficacy of Protracted Temozolomide in Patients With Progressive High Grade Glioma NCT00575887 | Marmara University | Phase 2 |
| Completed | The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma NCT00392171 | Merck Sharp & Dohme LLC | Phase 2 |
| Terminated | Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodend NCT00360828 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Terminated | Eligibility Screening of Patients With Central Nervous System Tumors for the National Cancer Institute s (NCI) NCT00035373 | National Cancer Institute (NCI) | — |
| Terminated | Genetic Analysis of Brain Tumors NCT00031538 | National Cancer Institute (NCI) | — |
| Completed | Prolonged Daily Temozolomide for Low-Grade Glioma NCT00165360 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Natural History of Patients With Brain and Spinal Cord Tumors NCT00009035 | National Cancer Institute (NCI) | — |
| Completed | Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide NCT00717210 | Neuro-Oncology Working Group of the German Cancer Society | Phase 3 |
| Completed | A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas NCT00080054 | Pharmacyclics LLC. | Phase 1 |